314 related articles for article (PubMed ID: 33025951)
1. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
3. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
Burke AC; Telford DE; Huff MW
Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
[TBL] [Abstract][Full Text] [Related]
4. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
5. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
6. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
[TBL] [Abstract][Full Text] [Related]
8. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
9. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
10. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
11. Mendelian Randomization Study of
Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
[TBL] [Abstract][Full Text] [Related]
12. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
14. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
[TBL] [Abstract][Full Text] [Related]
16. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
[TBL] [Abstract][Full Text] [Related]
17. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
[TBL] [Abstract][Full Text] [Related]
18. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
19. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
[TBL] [Abstract][Full Text] [Related]
20. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]